-
TONIGHT! Presentation on, ENJAYMO, the first and only approved treatment in Cold Agglutinin Disease1 at 6pmPT. Industry News
-
TOMORROW! Legislative Briefing on Cancer Prevention and Early Detection MOASC News/MOASC Programs & California News
-
Friday & Saturday! Hoag Oncology Nursing Conference MOASC News/MOASC Programs
-
ICER) receives grant from California Health Care Foundation to review unsupported drug price increases. California News
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
TOMORROW! Virtual Legislative Briefing on Cancer Prevention and Early Detection, Wednesday, March 9, 10:00AM – 11:00AM-Pacific. Moderated by: Autumn J. Ogden-Smith, Director, California State Legislation, American Cancer Society – Cancer Action Network, Inc.; Senator Susan Rubio (D-Baldwin Park) – Invited; The Impact of COVID on Cancer Care and the Path Forward presented by: Rana McKay, M.D., UC San Diego Moores Cancer Center; The Importance of Screening presented by: Margaret Hitchcock, PhD, California Colorectal Cancer Coalition (C4); How Delays in Screening Impact Patient Care presented by: Sukhmani Padda, M.D., Thoracic Medical Oncologist, Cedars-Sinai.
The goal of the California Cancer Caucus (CCC) is to develop a continuous line of communication and education between stakeholders and health policy decision makers, as a resource for all cancer related public policy. As the COVID-19 pandemic has swept across California, many patients delayed critical screening and diagnostic tests for detecting cancers. Due to delays, physicians are seeing more patients present with advanced stages of cancers that would have otherwise been detected earlier with standard screening practices. Keeping up with medical care and cancer screenings may contribute to the future health of Californians.
|
|
The Hoag Oncology Nursing Conference is virtual again this year. Word is, it is simply the best virtual oncology nursing event!
March 11-12, 2022 Hoag Oncology Nursing Conference
|
|
Don’t miss two upcoming MOASC Targeted Oncology Roundtables. The Virtual Case-Based Roundtable Meetings are a collaborative, small-group meeting designed around case-based clinical profiles and peer-dialogue led by an expert physician. This session offers practicing oncologists the perfect opportunity to sharpen their skills and expertise in treatment strategies. Attendees are paid $500 of compensation by Healthcare Research Analytics® for their attendance, participation & completion of the post-event HRA survey.
March 24, Program 1 is open to, and intended for, oncologists treating Myeloproliferative Neoplasms: Myelofibrosis and Polycythemia vera, at 7:00pm-8:30pm PT, moderated by Angela Fleischman, M.D. (UC Irvine)
|
|
April 28, Program 2 is open to, and intended for, oncologists treating GvHD: Acute and Chronic, at 7:00-8:30pm PT, moderated by Paul Carpenter, M.D. (Fred Hutchinson Cancer Research Center)
|
|
March 26, 2022 - MOASC’s 7th Annual Oncology Summit & Research Symposium at the Hyatt Regency in Huntington Beach. This LIVE Meeting will follow a multi-tumor approach with nationally recognized speakers, which will review personalized cancer care and current clinical trials in Breast, Gastrointestinal, Genitourinary, Lung, CAR-T/Transplant and Myeloma. This will be a great opportunity to learn from experts and network with colleagues.
|
|
MOASC is pleased to join Rockpointe in presenting “Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas.” Available until August 2022, this is an on-demand, free CME/CE-certified, webcourse available to MOASC members and to anyone who would like to participate
|
|
Career News
Sign up now to receive the MOASC Job Flash™! Please activate your new job alert.
|
|
MOASC Clinical Trial Database is on the MOASC website at www.moasc.org
|
|
TOMORROW! MOASC, ANCO and the California Cancer Caucus invite you to a Virtual Legislative Briefing on Cancer Prevention and Early Detection, Wednesday, March 9, 10:00am – 11:00am PT. Moderated by: Autumn J. Ogden-Smith, Director, California State Legislation, American Cancer Society – Cancer Action Network, Inc.; Senator Susan Rubio (D-Baldwin Park) – Invited; The Impact of COVID on Cancer Care and the Path Forward presented by: Rana McKay, M.D., UC San Diego Moores Cancer Center; The Importance of Screening presented by: Margaret Hitchcock, PhD, California Colorectal Cancer Coalition (C4); How Delays in Screening Impact Patient Care presented by: Sukhmani Padda, M.D., Thoracic Medical Oncologist, Cedars-Sinai.
The goal of the California Cancer Caucus (CCC) is to develop a continuous line of communication and education between stakeholders and health policy decision makers, as a resource for all cancer related public policy.
As the COVID-19 pandemic has swept across California, many patients delayed critical
screening and diagnostic tests for detecting cancers. Due to delays, physicians are seeing more patients present with advanced stages of cancers that would have otherwise been
detected earlier with standard screening practices. Keeping up with medical care and cancer
screenings may contribute to the future health of Californians.
|
|
The Institute for Clinical and Economic Review (ICER) has received a new grant from the California Health Care Foundation (CHCF) to develop 1) two annual unsupported price increase reports specific to California, and 2) a policymaker guide outlining how to use comparative effectiveness research to ensure that patients have fair access to fairly priced drugs.
Additionally, the CHCF grant will continue to fund ICER value assessments evaluated by the California Technology Assessment Forum (CTAF) a group of California health plan medical directors. California passed SB-17, a drug transparency law requiring manufacturers to report increases to prescription drugs' wholesale acquisition cost (WAC). ICER will leverage the annual SB-17 reports on brand and specialty drugs with the most significant year-over-year spending increases to evaluate whether there is new evidence that could justify the price increase (using the same methodology used for ICER’s annual unsupported price increase report at the national level).
Deadline is this Friday! The CalHealthCares Loan Repayment Program application deadline has been extended to March 11, 2022. CalHealthCares provides loan repayment on educational debt for California physicians and dentists who increase access to care to Medi-Cal patients. Eligible physicians can apply for a loan repayment award of up to $300,000 in exchange for a five-year service obligation. Eligible dentists can apply for a loan repayment award of up to $300,000 in exchange for a five-year service obligation or a Practice Support Grant of up to $300,000 in exchange for a 10-year service obligation. The program is funded by Proposition 56 voter-approved, tobacco tax revenues.
|
|
March 16, 2022, at 3 p.m., the Department of Managed Health Care (DMHC) invites you to a public meeting on Health Care Premium Rates and Prescription Drug Cost Transparency to be held in San Francisco and on the phone. The meeting will be conducted in person at the auditorium in the Milton Marks Conference Center at 455 Golden Gate Ave, Lower Level, San Francisco, CA 94102-3688. Members of the public are welcome to attend the meeting and provide public comments. Members of the public may listen into the meeting by calling toll-free at 1-888-566-5792 with participant passcode: 11413. You may submit public comment until 5 p.m. on March 26, 2022, to publiccomments@dmhc.ca.gov. For more information about this public meeting, please read the agenda or visit the Annual Meetings Webpage.
The California American Cancer Society Cancer Action Network report through February 24, 2022 can be read below.
|
|
Billing and Coding: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A57329) - R3 - Effective February 24, 2022. This Billing and Coding Article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).
|
|
MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38339) - R1 - Effective February 03, 2022. This Local Coverage Determination (LCD) has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).
|
|
Billing and Coding: MolDX: myPath® Melanoma Assay (A57626) - R3 - Effective January 01, 2022. This Billing and Coding Article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).
|
|
March 10, 2022 Local and National Coverage Determinations (LCD/NCD) - After Hours
webinar is intended for Medicare Part A and B Providers and will include: • Overview • National Coverage Determination (NCD) • Local Coverage Determination (LCD) • Medicare Coverage Database (MCD) • Resources.
|
|
March 17, 2022 Noridian Medicare Portal (NMP) Eligibility Webinar includes: Noridian Medicare Portal, Hours of Availability, Eligibility, MBI Look Up, Resources
|
|
March 29, 2022 Medicare Secondary Payer (MSP) Part B Billing
This webinar is intended for Part B providers and will include: • Part B Billing Options, Payments and Calculations • Overpayment Process • Forms and Noridian Medicare Portal (NMP) • Avoiding Delays • Resources.
|
|
March 30, 2022 - Telehealth Provider Enrolling in Medicare
Learn telehealth regulations and how to enroll in Medicare as a provider or supplier. Learn about eligible providers, originating sites, distant site practitioners, and what type of equipment for communication is necessary for compliance.
|
|
April 6, 2022, Physician Assistants and Practice Ownership Webinar includes: Physician Assistant Ownership Interest, Physician Assistant Enrolling in Medicare, Physician Assistant Enrolling as a Sole Proprietor, CMS 855I Initial Enrollment as a Physician Assistant, CMS 855 B Initial Enrollment as a Sole Owner - Physician Assistant, Electronic Funds Transfer Agreement, and Physician Assistant accepting reassignment as the employer
|
|
Read Medicare Learning Network Connects newsletter of March 3, 2022 for more information. |
|
Two researchers at Georgia Tech have developed a way to generate reliable breast tumor models faster and with less immune variability than existing methods, and their research may help scientists understand variations in treatment response. The researchers grew tumors in a gel-like matrix and controlled how immune cells filter into the tumor microenvironment, creating valuable models for testing immunotherapy drugs and replicating treatment-resistant breast cancer.
|
|
A ValuePenguin report found that US spending on prescription and over-the-counter drugs soared 77% from $322 billion to $570 billion between 2010 and 2020, while out-of-pocket costs for prescriptions fell from $48 billion to $47 billion during the same period. US households, on average, spent $4,571 per year on prescription drugs in 2019, with Delaware recording the highest spending per household at $6,513.
|
|
Affiliate Association News |
|
March 11-13, 2022, the 22nd Multidisciplinary Management of Cancers: A Case-based Approach returns to the Silverado Resort and Spa in Napa. The meeting is sponsored by the Association of Northern California Oncologists, Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center. Registration is now open for HCP for in person and virtual attendance.
|
|
March 17, 2022, 12:15pm PT, women leaders in oncology share their experiences with ANCO Connections: What It Is Like to be a Woman Oncology Leader Today.
|
|
Thursday, March 17, 2022, 5:00-6:30 p.m.ET, don't miss this year's virtual Satellite Symposia in conjunction with the 2022 Highlights of ASH featuring: Conversations and Commentaries®: Translating Evolving Data for the Use of BTK Inhibitors in CLL Into Clinical Practice.
|
|
Just A Week Away! Will You Be There? The 2022 Community Oncology Conference is two days, but the agenda is packed with all the information you need to know to beat challenges in the coming year. At this year’s Conference, learn about the needs of community oncology practices in the future and how you can incorporate these lessons into your own practice. Learn to address socioeconomic, racial, and ethnic differences, which greatly affect how care is provided and outcomes. Hear how practices work to address these problems. On March 17-18, oncology professionals from around the country will gather at the Gaylord Palms Hotel in Kissimmee, Florida for the best oncology conference in the country.
|
|
Please read the COA comment letter filed yesterday regarding the CMS proposed rule on DIR fees. COA says CMS proposal to address DIR Fees is a good first step, but Washington must do much more to end destructive fees and practices that drive up cost of cancer care.
|
|
The Leukemia & Lymphoma Society News |
|
The Leukemia & Lymphoma Society presents Advances in Multiple Myeloma. This free telephone/web Educational Program is Wednesday, March 16, 2022, 11:00am-12:30pm Pacific.
Learn more about: current and latest advances in treatment; Determining treatment for your myeloma; Managing side effects; The importance of communicating with your treatment team.
|
|
Bristol-Myers Squibb announced that the FDA approved nivolumab (Opdivo) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.
|
|
Merck announced that the Phase 3 KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resected stage IIB and IIC melanoma met its key secondary endpoint of distant metastasis-free survival (DMFS) at a pre-specified interim analysis. In the trial, adjuvant treatment with KEYTRUDA demonstrated a statistically significant improvement in the endpoint of DMFS compared to placebo in these patients. No new safety signals were observed.
|
|
Sanofi announced that FDA has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells (hemolysis).
|
|
Sanofi invites you to join tonight or one of their other upcoming virtual educational presentations entitled: ENJAYMO, the first and only approved treatment in Cold Agglutinin Disease1. Dates: Tuesday, March 8 at 6pm PST with Livia Hegerova, MD Swedish Cancer Institute in Seattle, Washington; Tuesday, March 15 at 6 pm EST with Hillary S. Maitland, MD, MS UVA Cancer Center in Charlottesville, Virginia; Thursday, March 17 at 6 pm CST with Jeremy Lorber, MD Tower Hematology Oncology in Los Angeles, California.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
